



NOTICE TO THE MARKET

JBS CONCLUDES THE ACQUISITION OF THE CONTROL OF BIOTECH FOODS AND ADVANCES IN THE CREATION OF A RD&I CENTER

JBS S.A. ("JBS" – B3: JBSS3; OTCQX: JBSAY), further to the Notice to the Market of November 17, 2021, communicates to its shareholders and to the market, that its controlled entity JBS Global Luxembourg S.à r.l. concluded on May 5, 2022, the acquisition of the control of the Spanish company BioTech Foods, S.L., one of the global leaders in the development of biotechnology for the production of cultivated protein.

BioTech Foods, S.L. will use the proceeds to finance its expansion plans. The company operates a pilot plant in the city of San Sebastián and expects to reach commercial production in mid-2024, with the construction of a new manufacturing unit, with an annual capacity of one thousand tons. Investment in the new facility is estimated at US\$41 million.

JBS also announces that it has chosen the city of Florianópolis-SC to host the JBS Biotech Innovation Center, a Research, Development and Innovation Center (RD&I) in Biotechnology, Food and Cultivated Protein in Brazil. The site will initially focus on the development of its own technology for the production of cultivated protein, aiming to make its production process more efficient, scalable and financially competitive. The investment to install the new RD&I Center is estimated at US\$60 million.

The acquisitions mark the Company's entry into the cultivated protein market, which consists of the production of food from animal cells, which are aligned with JBS's strategy of expanding its platform of new forms of protein production, as a reflection of new consumption trends and population growth in the coming decades.

São Paulo, May 09, 2022

Guilherme Perboyre Cavalcanti
Investor Relations Officer